Overall, our study uncovers a novel regulatory axis involving OGT-METTL3-HMGB1 that governs pancreatic cancer development and highlights the potential therapeutic strategy targeting ferroptosis and gemcitabine. The gene discussed is METTL3; the disease is familial pancreatic carcinoma.